LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Начало・Списък с акции・Organon & Co

Search

Organon & Co

Затворен

СекторЗдравеопазване

13.39 0.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.38

Максимум

13.39

Ключови измерители
By Trading Economics
Приходи	351M 146M
Продажби	-47M 1.5B
P/E Средно за сектора	14.376 49.888
EPS	0.71
Дивидентна доходност	0.6
Марж на печалбата	10
Служители	10,000
EBITDA	286M 351M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-7.85% downside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.60% 2.38%
Следващи печалби	4.08.2026 г.
Следваща дата на дивидент	11.06.2026 г.
Следваща дата на екс-дивидент	14.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	55M 3.5B
Предишно отваряне	13.24
Предишно затваряне	13.39

Настроения в новините

By Acuity

72%

28%

299 / 344 Класиране в Healthcare

Organon & Co Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.04.2026 г., 06:09 ч. UTC

Придобивния, сливания и поглъщания

India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal -- 2nd Update

27.04.2026 г., 02:33 ч. UTC

Придобивния, сливания и поглъщания

India's Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal - Update

27.04.2026 г., 01:04 ч. UTC

Придобивния, сливания и поглъщания

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

7.11.2025 г., 14:41 ч. UTC

Придобивния, сливания и поглъщания

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

27.04.2026 г., 18:07 ч. UTC

Придобивния, сливания и поглъщания

Organon Rides the Pharma M&A Wave With Sun Takeover. The Stock Sizzles. -- Barrons.com

27.04.2026 г., 15:14 ч. UTC

Придобивния, сливания и поглъщания

Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal -- Update

27.04.2026 г., 14:56 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27.04.2026 г., 13:58 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27.04.2026 г., 13:38 ч. UTC

Горещи акции

Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm -- WSJ

27.04.2026 г., 12:18 ч. UTC

Придобивния, сливания и поглъщания

Another Pharma Takeover Shows the Sector Is Hot. Organon Stock Rides the M&A Wave. -- Barrons.com

27.04.2026 г., 09:22 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. -- Barrons.com

27.04.2026 г., 00:38 ч. UTC

Придобивния, сливания и поглъщания

Sun Pharmaceutical to Acquire Organon Shares for $14.00 Each in an All Cash Deal

27.04.2026 г., 00:38 ч. UTC

Придобивния, сливания и поглъщания

Sun Pharmaceutical to Acquire Organon & Co. at an Enterprise Value of $11.75B

24.04.2026 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 17:09 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

10.04.2026 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10.04.2026 г., 14:39 ч. UTC

Придобивния, сливания и поглъщания

Update: This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10.04.2026 г., 14:01 ч. UTC

Придобивния, сливания и поглъщания

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10.04.2026 г., 09:23 ч. UTC

Горещи акции

Stocks to Watch Friday: Lumentum, Coherent, Porsche -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Organon & Co Прогноза

Ценова цел

By TipRanks

-7.85% надолу

12-месечна прогноза

Среден 12.33 USD -7.85%

Висок 14 USD

Нисък 9 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Organon & Co през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

0

Купи

4

Задържане

0

Продай

Според 4 анализатори, дали борсови рейтинги на Organon & Co през последните 3 месеца.

Настроение

By Acuity

299 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Други акции от сектора

LLY

Eli Lilly and Co.

1,125.18

JNJ

Johnson and Johnson

228.23

ABBV

AbbVie Inc

224.88

UNH

UnitedHealth Group Inc

396.79

MRK

Merck & Co Inc.

120.25

Live chat